Publicacións nas que colabora con Oreste Gualillo (64)

2023

  1. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Activation of Hypothalamic AMP-Activated Protein Kinase Ameliorates Metabolic Complications of Experimental Arthritis

    Arthritis and Rheumatology, Vol. 74, Núm. 2, pp. 212-222

  2. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  3. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  4. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib

    Journal of Ethnopharmacology, Vol. 272

  2. Pharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity

    Molecules (Basel, Switzerland), Vol. 26, Núm. 4

  3. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2020

  1. Adipokines and inflammation: Focus on cardiovascular diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 20, pp. 1-34

  2. Levels of the novel endogenous antagonist of ghrelin receptor, liver-enriched antimicrobial peptide-2, in patients with rheumatoid arthritis

    Nutrients, Vol. 12, Núm. 4

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170

  2. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue

    Pharmacological Research, Vol. 144, pp. 51-65

2018

  1. Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

    Endocrine, Vol. 60, Núm. 1, pp. 103-111

2016

  1. Endolysosomal two-pore channels regulate autophagy in cardiomyocytes

    Journal of Physiology, Vol. 594, Núm. 11, pp. 3061-3077

2015

  1. The adipokine chemerin induces apoptosis in cardiomyocytes

    Cellular Physiology and Biochemistry, Vol. 37, Núm. 1, pp. 176-192

2013

  1. Ghrelin requires p53 to stimulate lipid storage in fat and liver

    Endocrinology, Vol. 154, Núm. 10, pp. 3671-3679

  2. Nesfatin-1 in human and murine cardiomyocytes: Synthesis, secretion, and mobilization of GLUT-4

    Endocrinology, Vol. 154, Núm. 12, pp. 4757-4767

2011

  1. Aliskiren affects fatty-acid uptake and lipid-related genes in rodent and human cardiomyocytes

    Biochemical Pharmacology, Vol. 82, Núm. 5, pp. 491-504

  2. Expanding the adipokine network in cartilage: Identification and regulation of novel factors in human and murine chondrocytes

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 3, pp. 551-559

2010

  1. Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes

    Endocrinology, Vol. 151, Núm. 7, pp. 3286-3298